EPS Holdings Inc. | Income Statement

Fiscal year is October-September. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
37,584
41,801
45,202
52,703
60,482
65,769
Cost of Goods Sold (COGS) incl. D&A
27,398
29,602
31,940
37,175
41,406
42,469
Gross Income
10,186
12,199
13,262
15,528
19,076
23,300
SG&A Expense
6,689
8,011
8,283
9,398
11,484
16,106
EBIT
3,498
4,188
4,979
6,481
7,592
7,194
Unusual Expense
411
59
677
18
51
149
Non Operating Income/Expense
419
3
304
355
492
143
Interest Expense
25
34
33
33
40
18
Pretax Income
3,437
4,252
4,542
6,758
8,034
7,228
Income Tax
1,607
2,290
2,487
2,719
3,057
2,637
Consolidated Net Income
1,830
1,962
2,055
4,038
4,977
4,590
Net Income
1,710
1,828
2,163
3,966
4,664
4,388
Net Income After Extraordinaries
1,710
1,828
2,163
3,966
4,664
4,388
Net Income Available to Common
1,710
1,828
2,163
3,966
4,663
4,388
EPS (Basic)
47.81
51.55
58.15
92.31
101.15
95.66
Basic Shares Outstanding
36
35
37
43
46
46
EPS (Diluted)
47.81
51.55
58.15
92.31
101.15
95.66
Diluted Shares Outstanding
36
35
37
43
46
46
EBITDA
4,137
4,969
5,800
7,787
9,452
9,173
Other Operating Expense
-
-
-
351
-
-
Non-Operating Interest Income
22
48
82
39
66
58
Minority Interest Expense
120
134
108
72
313
202
Equity in Affiliates (Pretax)
66
7
113
67
26
-

About EPS Holdings

View Profile
Address
Kagurazaka AK Building, 6/F
Tokyo Tokyo 162
Japan
Employees -
Website http://www.eps-holdings.co.jp
Updated 07/08/2019
EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin and Others. The CRO segment offers clinical trials, data management, and statistical analysis.